ArticleNPJ systems biology and applications2026
Network modeling of sporadic colorectal cancer reveals the importance of off-target effects of Cyclooxygenase inhibitors.
Article in NPJ systems biology and applications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclooxygenase (COX) inhibitors (COXIBs) have shown preventive and therapeutic potential for colorectal cancer (CRC). In addition to inhibiting COX, approved COXIBs also target COX-independent pathways, including NF-κB and AKT. We evaluated how inhibition of various COXIB targets affects cell proliferation and apoptosis using a Boolean model incorporating the effect of several genetic mutations linked to CRC. The mutations activate two positive feedback loops and cause increased cell proliferation and survival. When simulating loss of function of APC, proliferation and apoptosis can be restored to healthy rates by inhibiting COX2. In simulations reflecting other genetic mutations, none of the investigated targets restore apoptosis and proliferation is reduced by inhibiting AKT or NF-κB, but not by any of the other COX targets tested. These results show that the off-target effects of COXIBs are crucial for their efficacy in the treatment of sporadic CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.